Related Experiment Video

Updated: Jun 2, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons

Jeong Sook Kim-Han1, Jo Ann Antenor-Dorsey, Karen L O'Malley

  • 1Department of Anatomy and Neurobiology, Washington University School of Medicine, Saint Louis, Missouri 63110, USA.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|May 13, 2011
PubMed

Insights

Parkinson's disease may involve impaired axonal transport. Neurotoxin exposure disrupted dopamine neuron mitochondria, but antioxidants like N-acetyl-cysteine protected axons.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Neurodegenerative Diseases

Background:

  • Impaired axonal transport is a potential factor in Parkinson's disease (PD) pathogenesis.
  • Dopamine (DA) neurons are critically affected in PD, making their axonal health a key research area.

Purpose of the Study:

  • To investigate the role of axonal transport in PD using a novel microchamber system.
  • To determine the specific effects of the neurotoxin 1-methyl-4-phenylpyridinium ion (MPP+) on dopamine neuron axonal transport.

Main Methods:

  • Utilized a microchamber system to isolate axons from cell bodies of green fluorescent protein-labeled mouse dopamine neurons.
  • Challenged segregated axons with the neurotoxin MPP+ and analyzed mitochondrial transport dynamics.
  • Investigated the involvement of various cellular pathways and the efficacy of antioxidant treatments.

Main Results:

  • MPP+ significantly reduced mitochondrial motility in DA axons, slowing anterograde and increasing retrograde transport.
  • These effects were specific to DA mitochondria and were independent of ATP, calcium, free radicals, JNK, or caspase3/PKC pathways.
  • The thiol-antioxidant N-acetyl-cysteine and glutathione completely blocked MPP+-induced mitochondrial dysfunction and rescued axonal degeneration.

Conclusions:

  • Axonal transport, particularly of dopamine neuron mitochondria, is a vulnerable target in Parkinson's disease.
  • Antioxidant therapies show promise for protecting axons from neurotoxin-induced damage.
  • Therapeutic strategies for PD should consider targeting both cell bodies and axons to preserve neural circuitry and function.

More Related Videos

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia07:32

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia

Published on: February 9, 2020

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...